Share This Page
Drugs in ATC Class L01XB
✉ Email this page to a colleague
Drugs in ATC Class: L01XB - Methylhydrazines
| Tradename | Generic Name |
|---|---|
| MATULANE | procarbazine hydrochloride |
| >Tradename | >Generic Name |
ATC L01XB (Methylhydrazines) Market Dynamics and Patent Landscape: Which Patents Still Matter for Oncology IVT Drugs?
ATC Class L01XB (“methylhydrazines”) covers a narrow set of oncology small molecules centered on procarbazine. In practice, the commercial IP and generic/biosimilar risk for this ATC bucket is driven by (1) Orange Book-style small-molecule patent estates for procarbazine products in the US, and (2) how long active and process/formulation patents were enforced or remain unexpired across jurisdictions. The dominant market dynamics are (a) mature generics in most markets where regulatory exclusivity has lapsed, and (b) ongoing life-cycle protection typically limited to formulation and manufacturing method claims rather than core active-ingredient composition claims.
Core business takeaway: for L01XB, “patent landscape work” is mostly about identifying whether any unexpired patents still cover (i) specific formulations (salt/form), (ii) granulation/sterilization/lyophilization-like process steps where applicable, or (iii) use-related claims that map to approved indications and label wording. For procarbazine, most composition patents are long past expiry in major jurisdictions, so generic entry risk is usually governed by whether any later-expiring formulation/process or packaging-related patents remain in force.
What drugs are included in ATC L01XB “methylhydrazines,” and where do they compete in oncology?
ATC code L01XB groups “methylhydrazines,” with procarbazine as the key active ingredient. L01XB products are used mainly in combination regimens in oncology.
Procarbazine: common therapeutic positioning
Procarbazine is historically used in regimens for:
- Hodgkin lymphoma
- Non-Hodgkin lymphoma (specific regimens vary by geography and standard-of-care)
- Other hematologic oncology combinations depending on local label and compendial use
How the market typically behaves
- Combination utilization means drug demand tracks regimen prevalence rather than monotherapy adoption.
- Product competition is heavily influenced by supply continuity and cost because mature generics compress pricing.
- When shortages occur, brand-like pricing temporarily resurges, but that rarely changes the structural patent expiry picture.
What patents protect procarbazine (L01XB) in the US, and how do they typically expire?
For L01XB, patent protection is usually a stack:
- Active ingredient composition patents (often oldest, earliest expiry)
- Formulation patents (later expiry)
- Manufacturing/process patents (later expiry)
- Method-of-use patents (sometimes, but less common when the molecule is old)
Typical procarbazine patent lifecycle pattern
- Composition claims for procarbazine generally filed decades earlier.
- When that expires, later patents tend to address:
- specific dosage forms (including excipient systems and stability profiles)
- manufacturing processes improving yield/stability or reducing impurities
- packaging constraints or specific product presentations
Exclusivity timelines that matter for small molecules
For procarbazine-type compounds:
- If there was older brand data exclusivity, it generally predates modern generic entry frameworks.
- In the US, Orange Book-listed patents (composition, formulation, method-of-use) are the controlling layer for ANDA/Paragraph IV strategy.
Featured-snippet answer: In L01XB, the “last patents that matter” are usually formulation and process rather than core composition, and they align with whatever remains listed and unexpired in the Orange Book for specific dosage forms.
When does procarbazine lose exclusivity, and what are the practical generic entry windows?
For L01XB, the controlling question is not “how long exclusivity lasts in theory,” but “what unexpired patents still cover the specific dosage form being referenced by an ANDA.”
Practical generic entry model
- Once all Orange Book patents tied to a reference listed drug (RLD) expire or are successfully challenged, generic entry can occur quickly.
- If any formulation or method-of-use patents remain, ANDA applicants may pursue Paragraph IV as a bet on invalidity/non-infringement, or wait out expiration.
What to look for in entry timing
- Patent-by-patent expiration dates
- Whether patents are jointly held across multiple RLD strengths/presentations
- Whether the ANDA strategy is “launch immediately at expiry” versus “settlement-driven early entry”
How many patents cover procarbazine formulations, and what is the split between composition, formulation, and process?
In mature oncology small molecules, the number of active claims in force at any point tends to be modest, but this depends on:
- ongoing life-cycle filings in the relevant jurisdictions
- whether regulators list patents broadly or narrowly for each RLD strength
Patent-type split businesses should model
- Composition of matter: usually outlasts by far the latest expiry if present, but for old oncology molecules it is often fully expired.
- Formulation: often the most common surviving stack element at late stages.
- Manufacturing/process: can survive if it is tied to a specific impurity profile or stability improvement.
- Method-of-use: survives if claims were drafted to match a specific regimen or regimen component on-label.
Featured-snippet answer: For L01XB/procarbazine, the active estate at late dates typically consists of a smaller number of formulation/process patents, with composition claims generally expired.
What Orange Book status applies to procarbazine, and which patents are listed per dosage form?
The Orange Book is the operational map for US generic launch:
- RLD name
- Strength and dosage form
- Patent numbers listed
- Patent expiration dates
- Patent types (e.g., composition, formulation, method of use)
How this affects ANDA/Paragraph IV
- ANDA filers reference the RLD and certify against listed patents.
- If a patent remains “unexpired,” the applicant chooses:
- ANDA with “Paragraph IV” (if strategically challenged)
- non-Paragraph IV (wait until expiration)
Business monitoring checklist
- Identify:
- Which procarbazine RLD entries carry still-unexpired patents
- Whether those patents are formulation or method-of-use
- Whether there are multiple listings covering different strengths
Which companies sell procarbazine in the US or major EU markets, and how does their patent posture affect pricing?
For mature small molecule oncology drugs like procarbazine, market power comes from:
- supply chain capacity (including sterile handling and packaging)
- manufacturing approvals
- the presence or absence of competing generics
Generic-led dynamics
- Once multiple ANDAs are approved, pricing typically moves toward cost-plus margins.
- When the market has limited competitors or periodic supply issues, pricing can deviate upward independent of patents.
Patent posture
Even if patents are mostly expired, companies still manage:
- regulatory exclusivity around their specific approvals
- product-specific life-cycle patents in some markets
- manufacturing process IP that may block “drop-in” generics under certain technical constraints
What patent litigation affects procarbazine (L01XB), including Paragraph IV and settlements?
In L01XB, litigation, when present, tends to cluster around:
- last-unexpired Orange Book patents (formulation/process)
- narrow infringement theories tied to excipient system or manufacturing steps
Typical litigation outcomes
- Dismissal/settlement where the challenger agrees to a date
- Launch-at-risk where patents are held invalid or not infringed
- Narrow settlement limiting design-around claims
Featured-snippet answer: For older oncology small molecules, most meaningful disputes are about the remaining formulation/process patents, and settlement structures often reflect a “generic launch date” rather than a full end-state invalidation of every patent.
How does procarbazine formulation patenting impact ANDA “design-around” options?
ANDA design-around risk is driven by what the surviving patents claim:
- If claims are tied to a specific excipient system or stability profile, redesign can be costly.
- If claims are tied to impurity specifications or specific process parameters, an applicant may redesign the process but still face chemistry-to-infringement analysis.
Key infringement vectors to model
- whether the claim is a “composition formula” (ingredients and ratios)
- whether it is a “process step” (e.g., order of addition, drying conditions, sterilization handling)
- whether it is tied to an end product attribute that is hard to replicate
What method-of-use patents exist for methylhydrazines, and do they block generic competition?
Method-of-use patents matter only when:
- the claims are tied to the actual labeled or compendial use
- the ANDA’s proposed labeling would infringe
Business impact
- If method-of-use patents remain active, generic entry may be delayed for specific indications.
- Label carve-outs or “skinny labeling” strategies can sometimes mitigate risk but depend on:
- claim scope
- whether an Orange Book method-of-use patent is listed as applicable to the RLD
Featured-snippet answer: For older methylhydrazines, method-of-use patents are less commonly the decisive barrier than formulation/process patents, unless a late-life filing aligned tightly to active label language.
What are the supply and manufacturing IP barriers for procarbazine, and how do they interact with patents?
Supply constraints for chemotherapy agents often depend on:
- raw material sourcing
- manufacturing capability for small-dose stability requirements
- batch reproducibility and impurity control
How process patents and regulatory requirements intersect
- Even if patents are expired, process know-how and validated operating ranges can restrict easy entry.
- If any process patents remain, a generic may need:
- alternative process routes
- new analytical validation to avoid prohibited impurity profiles
- different manufacturing conditions to reduce infringement risk
How does procarbazine compare with other ATC L01BX alternatives in patent/market risk?
Within broader oncology chemotherapy, alternatives typically cluster around:
- other older alkylating agents and combination partners
- newer targeted or immune therapies that may reduce long-term demand
Patent risk comparison framework
- Older classic chemotherapies: typically low patent risk today on composition; residual risk from formulation/process and limited method-of-use claims.
- Newer agents: higher patent density and stronger regulatory exclusivity layers.
Featured-snippet answer: For ATC L01XB, the relative patent risk is usually lower than newer oncology classes because the active ingredient is historically mature. Residual risk is mainly about late-expiring formulation/process patents tied to specific RLD presentations.
What biosimilar or biologics risk applies to ATC L01XB methylhydrazines?
ATC L01XB is a small-molecule chemotherapy class. It does not present biosimilar pathways.
Featured-snippet answer: Biosimilar risk does not apply; the competition channel is ANDA generics (US) and generic marketing authorizations (EU and other jurisdictions).
Which jurisdictions remain most important for enforcing procarbazine patents, and what is the enforcement pattern?
Enforcement tends to follow:
- where key markets have still-unexpired formulation/process patents
- where regulatory listing is strong (e.g., US Orange Book, EU patent enforcement and SPC ecosystems)
Jurisdiction-specific enforcement pattern
- US: Paragraph IV and district court infringement cases driven by Orange Book listings.
- EU: enforcement through national courts and potential patent/SPC structures where applicable.
Revenue exposure: how sensitive are L01XB methylhydrazine sales to generic erosion?
For mature L01XB drugs, revenue sensitivity is typically high once:
- at least two to three additional generic competitors enter, and
- no remaining patents block them
Commercial model
- Pre-expiry: brand-like or single-generic dynamics can keep prices higher.
- Post-expiry: rapid price compression is typical.
- Supply shortages can temporarily disrupt this but do not change patent expiry mechanics.
Key Takeaways
- ATC L01XB (“methylhydrazines”) is effectively a procarbazine-driven landscape, with generic market structure largely determined by US Orange Book-listed patents and similar national listing systems.
- The patent estate that can still block competition late in the lifecycle is usually formulation and manufacturing/process, not core composition.
- Generic entry timing is governed by the last unexpired, listed patents per specific dosage form/RLD, with litigation and settlements typically centered on those remaining claims.
- Biosimilar risk is not applicable because L01XB methylhydrazines are small molecules, not biologics.
FAQs
Do procarbazine generics face Paragraph IV risk, or is the class largely free of active Orange Book barriers?
Paragraph IV risk is present only to the extent that unexpired Orange Book patents are listed for the relevant procarbazine RLD/strength/dosage form.
Can a generic enter with “skinny labeling” if a method-of-use patent is still listed for procarbazine?
Skinny labeling can mitigate method-of-use infringement risk when claims map to indication-specific label language covered by the Orange Book method-of-use listing.
What formulation changes most often support a generic “design-around” for older oncology small molecules?
Excipient-system changes, solid-state property targeting, and process parameter redesign that avoids claimed process steps or end-product attributes.
Does supply disruption matter more than patents for procarbazine pricing?
Supply disruptions can drive short-term pricing, but long-term pricing typically follows patent expiry and the number of approved generic competitors.
Is procarbazine protected by patent terms in EU via SPC mechanisms?
Where eligible, SPCs can extend patent-like exclusivity in EU markets, shifting generic entry timing, but enforcement still depends on unexpired, enforceable national rights for the specific product presentation.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- World Health Organization. ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
More… ↓
